Sanofi bucks unit-sale trend with plan to unload $7B worth of older products

Sanofi CEO Chris Viehbacher

While other companies are hiving off large pieces of their operations to get fit and focused, Sanofi ($SNY) has decided to simply clean out its closet. By selling off a number of older products, it can make room for the kind of bolt-on deals that CEO Chris Viehbacher said on Tuesday interest him. Report

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.